Evidence map›Paper›PMID 30584137›Full record

ArticleJournal of Alzheimer's disease : JAD2019

Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project.

John Gallacher, Frederic de Reydet de Vulpillieres, Billy Amzal, Zuzanna Angehrn, Christin Bexelius, Christophe Bintener, Jacoline C Bouvy, Laura Campo, Carlos Diaz, Jean Georges and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Generating real-world evidence in Alzheimer's disease: Considerations for establishing a core dataset.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Health economic modeling for Alzheimer's disease: Expert perspectives.Alzheimer's & dementia (New York, N. Y.) · 2022
    Article
  9. Article
  10. Review
  11. Conducting public involvement in dementia research: The contribution of the European Working Group of People with Dementia to the ROADMAP project.Health expectations : an international journal of public participation in health care and health policy · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

John GallacherDepartment of Psychiatry, University of Oxford, Oxford, UK.
Frederic de Reydet de VulpillieresNovartis Pharma AG, Basel, Switzerland.
Billy AmzalAnalytica Laser, London, UK.
Zuzanna AngehrnAnalytica Laser, London, UK.
Christin BexeliusF. Hoffmann-La Roche, Basel, Switzerland.
Christophe BintenerAlzheimer Europe, Luxembourg, Luxembourg.
Jacoline C BouvyNational Institute for Health and Care Excellence (NICE), London, UK.
Laura CampoEli Lilly Italy S.p.A., Sesto Fiorentino, Italy.
Carlos DiazSynapse Research Management Partners SL, Barcelona, Spain.
Jean GeorgesAlzheimer Europe, Luxembourg, Luxembourg.
Alastair GrayNuffield Department of Population Health, University of Oxford, Oxford, UK.
Antje HottgenrothLilly Deutschland GmbH, Bad Homburg, Germany.
Pall JonssonNational Institute for Health and Care Excellence (NICE), London, UK.
Brent MittelstadtOxford Internet Institute, University of Oxford, Oxford, UK.
Michele H PotashmanBiogen, Cambridge, MA, USA.
Catherine ReedEli Lilly and Company Ltd., Windlesham, UK.
Cathie SudlowUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
Robin ThompsonBiogen, Zug, Switzerland.
Antje Tockhorn-HeidenreichEli Lilly and Company Ltd., Windlesham, UK.
Andrew TurnerBiogen, Cambridge, MA, USA.
Johan van der LeiDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.
Pieter Jelle VisserMaastricht University, Maastricht, and VU University Medical Center, Amsterdam, Netherlands.
ROADMAP Consortium

Funding

Department of HealthMedical Research Council MR/009076/1Medical Research Council MR/L023784/1
6 · The paper itself

Abstract

ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

Indexed as

Evidence-Based MedicineAgedAged, 80 and overAlzheimer DiseaseClinical Decision-MakingCost-Benefit AnalysisData Interpretation, StatisticalHumansTreatment OutcomeAlzheimer’s diseasedata sharingdata systemshealth policypatient outcome assessmentreal-world clinical trialssystems integration

Identifiers

PMID30584137
PMCPMC6398537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.